

Vesugen Available for Research Use Only

(Speculative, community-informed subcutaneous pattern: 200 mcg/day for 10–20 days)

Vesugen (KED; Lys–Glu–Asp) is a synthetic tripeptide studied for vascular regulation and neuroprotection. It belongs to the Khavinson short-peptide bioregulator research program and is not a classical receptor agonist. Cell experiments support plausible endothelial effects, and small Russian clinical reports describe improved peripheral and penile arterial blood flow. Mouse and human-cell studies also suggest protection of neuronal structures. Increased proliferation markers in cell cultures raise a theoretical concern in cancer-related settings, rather than demonstrating that Vesugen causes cancer. [1–9]

 Human safety insufficiently characterized; long-term and injected-use safety unresolved.

 Plausible vascular benefits; likely selected neuronal structural protection based on animal evidence. [1,4–6,8,9]

Disclaimer: These notes are not authoritative and should not be interpreted as definitive scientific guidance. They are summaries, compilations and plausible extrapolations drawn from the most relevant research I was able to locate, and may omit nuances, conflicting data, or emerging evidence. The material reflects an attempt to organize and understand complex topics, not to provide clinical recommendations or expert interpretation.

This document was updated 13-Oct-26. A published version of this survey is available at <https://pdfs.researcher6076.com/pdfs/vesugen.pdf>



Small regional studies provide limited short-course experience. Long-term safety and the safety of repeated subcutaneous courses is unknown. A small geriatric study reported prooxidant laboratory changes and fewer circulating CD34-positive cells; the clinical significance is uncertain. [5–7,10]

Endothelial findings are principally laboratory observations. Small clinical reports support plausible vascular benefits, while neuronal structural protection has animal and cell support. [1,2,4–9]

How Evidence Scope Was Applied in This Review

For Vesugen, most human claims originate from small regional reports, occupational studies, peptide combinations, or later reviews rather than accessible randomized trials of Vesugen alone. Those findings are treated as evidence, but they do not receive the same weight as well-controlled and independently replicated human research.

Dosage & Patterns

Oral-product use and mouse intraperitoneal dosing do not provide a reliable conversion to a human subcutaneous dose. [4,10]

Vesugen Available for Research Use Only

(Speculative, community-informed subcutaneous pattern: 200 mcg/day for 10–20 days)

Russian oral-product instructions: The supplier describes 1–2 capsules, 1–2 times daily with food for 10–30 days, with repeat courses after 4–6 months. These are commercial product instructions, not an independently validated treatment schedule. The capsule contains the AC-2 complex and excipients; its total capsule weight is not the mass of purified KED. [10]

- **200 mcg/day for 10–20 days is a common, speculative, community-informed subcutaneous pattern.** This dose is not a verified original research regimen. Neither the proposed brief biological pulse nor annual repetition has been established in human pharmacokinetic or dose-finding studies.

Some community discussions, occur around higher doses of 0.5–2 mg/day for 4–12 or more weeks. These unverified proposals do not establish a safe escalation schedule or a superior effect.

Pattern Notes

Vesugen is discussed alongside Epitalon, Prostamax, and other **Khavinson short-peptide bioregulator peptides** using either overlapping or sequential courses. This describes community practice rather than a tested combination regimen.

Benefits

- **Plausible endothelial support.** Vesugen altered endothelin-1, connexin, and SIRT1 expression in cultured vascular endothelium. These findings support a vascular-regulation hypothesis rather than demonstrating generalized microcirculatory improvement in people. [1]
- **Plausible preservation of selected neuronal structures.** In a single study Vesugen reduced dendritic-spine loss in a mouse Alzheimer model. The electrophysiological improvement was a nonsignificant trend, so it should not be presented as established restoration of learning or memory. The publication's duplicated images were corrected in 2025, with the authors reporting unchanged conclusions. [4,8]
- **Plausible support for neuronal branching.** Vesugen increased dendritic branching in induced neurons made from older human donors' fibroblasts. This is a human-cell experiment, not a treatment trial or evidence of rejuvenation in people. [9]
- **Plausible improvement in peripheral perfusion and vascular erectile function.** Small Russian reports describe favorable blood-flow and clinical changes. Their limited designs and reporting justify cautious interpretation rather than a general efficacy claim. [5,6]

Plausible Functional Endpoints Around Healthspan

The most relevant functional possibilities are walking comfort and vascular erectile function. Cognitive benefit remains an extrapolation from neuronal findings and exploratory clinical observations. These possibilities should retain the same qualifications as the evidence supporting them. [4–7,9]

Vesugen Available for Research Use Only

(Speculative, community-informed subcutaneous pattern: 200 mcg/day for 10–20 days)

- **Plausibly better walking tolerance in peripheral arterial insufficiency.** A small report in patients previously operated on for chronic lower-limb ischemia described clinical and ultrasound improvement after Vesugen. [6]
- **Plausibly improved erectile quality in vascular erectile dysfunction.** A small report described improvement in symptoms and penile arterial flow. [5]
- **Plausible cognitive support.** Neuronal structural findings provide a biological rationale, and a small geriatric report described changes in functional and biological-age indicators. [4,7,9]

Investigational Uses

- **Endothelial regulation and vascular aging** are research targets supported by cell experiments. [1,2]
- **Peripheral arterial insufficiency, vascular erectile dysfunction, and neuronal resilience** are investigational applications, with evidence ranging from small clinical reports to animal and cell studies. [4–7,9]

Cautions and Contraindication Considerations

- **Cancer or antiangiogenic therapy: Proliferation-related caution:** Vesugen increased Ki-67 in cultured cells. The relevance to occult tumors or concurrent cancer therapy is unresolved. Proliferation findings warrant individualized review before experimental use. This is a mechanism-based precaution. [2]
- **Unstable cardiovascular disease:** New chest pain, rapidly worsening limb symptoms, or other signs of acute ischemia require clinical assessment rather than an experimental peptide course.
- **Concurrent treatment:** Interactions with vasodilators, blood-pressure drugs, antiplatelets, anticoagulants, and other peptides are insufficiently characterized. Medication review is appropriate; no specific bleeding interaction is established by the cited Vesugen literature.
- **Pregnancy and breastfeeding safety** are also unresolved.

Drivers of Diminished Response and Mitigation Strategies

Specific risks of receptor desensitization and neutralizing antibodies are likely not applicable to Vesugen. Downstream adaptation has not been evaluated for Vesugen. [3]

Biological Mechanism

Vesugen consists of lysine, glutamic acid, and aspartic acid. Its proposed action involves regulation of cellular gene expression. In endothelial cultures, Vesugen changed endothelin-1, connexins, and SIRT1; another study found higher Ki-67 and used molecular docking to propose interaction with the MKI67 promoter. Docking is a mechanistic hypothesis, not proof of promoter binding or target engagement in a treated person. Neuronal experiments show effects on dendritic structure, suggesting activity beyond the vascular compartment. The most defensible model is context-dependent cellular regulation, with human pharmacokinetics and the connection between these laboratory effects and clinical benefit still unresolved. [1–4,9]

Conclusions

Vesugen has plausible vascular applications supported by endothelial experiments and small clinical reports. Selected neuronal structural effects have animal support, with additional human-cell findings. These observations justify research but do not establish likely anti-aging efficacy, reliable subcutaneous dosing, or long-term safety. [1–10]

References

1. Kozlov KL, Bolotov II, Linkova NS, Drobintseva AO, Khavinson VKh, Dyakonov MM, Kozina LS. Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis. *Adv Gerontol.* 2016;29(4):646–650. Russian-language endothelial laboratory study; PMID:28539025. [Source](#)
2. Khavinson VKh, Tarnovskaia SI, Linkova NS, Guton EO, Elashkina EV. Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging. *Adv Gerontol.* 2014;27(1):108–114. Cell-culture and molecular-docking study; PMID:25051766. [Source](#)
3. Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide regulation of gene expression: a systematic review. *Molecules.* 2021;26(22):7053. Mechanistic context, not a clinical efficacy trial. [doi:10.3390/molecules26227053](https://doi.org/10.3390/molecules26227053)
4. Khavinson V, Ilina A, Kraskovskaya N, Linkova N, Kolchina N, Mironova E, Erofeev A, Petukhov M. Neuroprotective effects of tripeptides—epigenetic regulators in mouse model of Alzheimer’s disease. *Pharmaceuticals.* 2021;14(6):515. Mouse and mechanistic study; read with correction [8]. [doi:10.3390/ph14060515](https://doi.org/10.3390/ph14060515)
5. Kitachev KV, Sazonov AB, Kozlov KL, Petrov Klu, Sliusarev AS, Khavinson VKh. [The efficacy of peptide bioregulators of vessels in lower limbs chronic arterial insufficiency treatment in old and elderly people]. *Adv Gerontol.* 2014;27(1):156–159. PMID:25051774. Indexed English title retained; the abstract describes 41 patients with vasculogenic erectile dysfunction and penile blood-flow measurements. Abstract-level assessment; dose and route not established from this record. [Source](#)
6. Kitachov KV, Sazonov AD, Kozlov KL, Petrov KYu, Slusarev AS, Sedova EV. The role of vasoactive peptid in lower limbs chronic arterial insufficiency treatment. *Adv Gerontol.* 2013;26(2):292–296. PMID:28976154. Russian-language report involving 41 previously operated patients; abstract-level assessment. Publication year is 2013, despite later PubMed indexing. [Source](#)
7. Meshchaninov VN, Tkachenko EL, Zharkov SV, Gavrilov IV, Katyreva IuE. Effect of synthetic peptides on aging of patients with chronic polymorbidity and organic brain syndrome of the central nervous system in remission. *Adv Gerontol.* 2015;28(1):62–67. PMID:26390612. Exploratory Vesugen/Pinealon report; abstract has inconsistent participant totals and does not adequately establish allocation, dose, or route. [Source](#)
8. Khavinson V, Ilina A, Kraskovskaya N, et al. Correction: Khavinson et al. Neuroprotective effects of tripeptides—epigenetic regulators in mouse model of Alzheimer’s disease. *Pharmaceuticals* 2021, 14, 515. *Pharmaceuticals.* 2025;18(1):111. Corrects duplicated Figures 5 and 8; authors report unchanged conclusions. [doi:10.3390/ph18010111](https://doi.org/10.3390/ph18010111)

Vesugen Available for Research Use Only

(Speculative, community-informed subcutaneous pattern: 200 mcg/day for 10–20 days)

9. Kraskovskaya N, Linkova N, Sakhenberg E, et al. Short peptides protect fibroblast-derived induced neurons from age-related changes. *Int J Mol Sci.* 2024;25(21):11363. Human donor-derived cell experiment, not a clinical trial. [doi:10.3390/ijms252111363](https://doi.org/10.3390/ijms252111363)
10. PEPTIDES. Vesugen: Russian oral-product composition and directions. Supplier information, accessed October 7, 2026. Supports description of the commercial formulation and labeled schedule only; promotional efficacy and safety claims are not independent clinical evidence. [Source](#)